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Telomeres, consisting of TTAGGG nucleotide repeats and a protein complex at chromosome ends, are critical for maintaining
chromosomal stability. Genomic instability, following telomere crisis, may contribute to breast cancer pathogenesis. Many genes
critical in telomere biology have limited nucleotide diversity, thus, single nucleotide polymorphisms (SNPs) in this pathway could
contribute to breast cancer risk. In a population-based study of 1995 breast cancer cases and 2296 controls from Poland, 24 SNPs
representing common variation in POT1, TEP1, TERF1, TERF2 and TERT were genotyped. We did not identify any significant
associations between individual SNPs or haplotypes and breast cancer risk; however, data suggested that three correlated SNPs in
TERT ( 1381C4T,  244C4T, and Ex2-659G4A) may be associated with reduced risk of breast cancer among individuals with a
family history of breast cancer (odds ratios 0.73, 0.66, and 0.57, 95% confidence intervals 0.53–1.00, 0.46–0.95 and 0.39–0.84,
respectively). In conclusion, our data do not support substantial overall associations between SNPs in telomere pathway genes and
breast cancer risk. Intriguing associations with variants in TERT among women with a family history of breast cancer warrant follow-up
in independent studies.
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Telomeres, located at the ends of chromosomes, consist of long
TTAGGG nucleotide repeats and an associated protein complex.
Chromosome ends are protected from end-to-end fusion and
degradation by this telomere complex, termed shelterin (de Lange,
2005). The TTAGGG repeats shorten with each cell division, and
eventually reach a critical state, at which time cellular senescence
and/or apoptosis is normally triggered (Rodier et al, 2005).
Tumour cells may survive cellular crisis in the absence of
chromosomal stability through the activation or inactivation of
alternative pathways. Breast cancer fits the paradigm of dysfunc-
tional telomere-induced genomic instability, because the transition
of breast duct hyperplasia to ductal carcinoma in situ likely results
from a period of telomere crisis (DePinho, 2000; Chin et al, 2004).
As breast cancer progresses further to invasive and metastatic
stages, telomere dysfunction and genomic instability become more
apparent (Nishizaki et al, 1997; Buerger et al, 1999; Chin et al,
2004). As cells progress through the latter stages of carcinogenesis,
telomeres become relatively stable. In addition, low-telomere DNA
content was found to be an independent predictor of decreased
survival in comparisons of breast cancer specimens to normal
tissues (Chin et al, 2004; Fordyce et al, 2006).
Most genes involved in telomere biology are highly conserved
between species and have limited nucleotide diversity in humans
(de Lange, 2004; Savage et al, 2005). We hypothesized that
common genetic variation (minor allele frequency (MAF) greater
than 5%) in the form of single nucleotide polymorphisms (SNPs)
in these genes could affect cancer risk. This hypothesis was
investigated in a population-based case–control study of breast
cancer study in Poland, in which we genotyped 24 common SNPs
that captured most of the common genetic variation in five genes
important in telomere biology. The studied genes included
telomerase (TERT (protein name), TERT (HUGO gene name),
5p15.33) (Collins and Mitchell, 2002), telomerase-associated
protein (TP1, TEP1, 14q11.2) (Poderycki et al, 2005), telomeric
repeat-binding factor 1 (TRF1, TERF1, 8q13) (Smogorzewska et al,
2000), telomeric repeat-binding factor 2 (TRF2, TERF2, 16q22.1)
(Chong et al, 1995; Broccoli et al, 1997) and protection of
telomeres 1 (POT1, POT1, 7q31.33) (Baumann and Cech, 2001).
MATERIALS AND METHODS
Study population
The design of this population-based breast cancer case–control
study has been described (Garcia-Closas et al, 2006a). Eligible
Received 28 March 2007; revised 19 July 2007; accepted 20 July 2007;
published online 14 August 2007
*Correspondence/Current address: Dr SA Savage, Clinical Genetics
Branch, Division of Cancer Epidemiology and Genetics, National Cancer
Institute, 6120 Executive Blvd., EPS/7018, Rockville, MD 20852, USA
E-mail: savagesh@mail.nih.gov
British Journal of Cancer (2007) 97, 832–836
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
scases included women aged 20–74 years who were Polish residents
of either Warsaw or Ło ´dz ´ with pathologically or cytologically
confirmed in situ or invasive breast cancer, newly diagnosed in
2000–2003. An estimated 90% of eligible cases were identified
through a rapid identification system at five participating
hospitals. Information from Cancer Registries was used to identify
the remaining 10% of eligible breast cancer cases. Eligible control
subjects were residents of Warsaw and Ło ´dz ´ who did not have a
history of breast cancer at enrollment. Controls were randomly
selected from population lists, and frequency-matched to breast
cancer cases by city and 5-year age groups. Women provided a
personal interview on known and suspected risk factors. Venous
blood samples were collected by a trained nurse. The study
protocol was reviewed and approved by local and National Cancer
Institute (NCI) Institutional Review Boards. All participants
provided written informed consent. Of the 3037 eligible cases
and 3639 eligible controls identified, 2386 (79%) cases and 2502
(69%) controls agreed to participate in the personal interview. The
present study is limited to women with blood DNA samples: 1995
cases (6% in situ) and 2296 controls, which represented 84 and
94%, respectively, of the study population.
Laboratory methods
Genomic DNA for genotype analyses was isolated from buffy coat
or whole blood samples using the Autopure LS
s DNA Purification
System (Gentra Systems Inc., Minneapolis, MN, USA). Twenty-
four SNPs in POT1, TEP1, TERF1, TERF2, and TERT were
genotyped by investigators blinded to case–control status, using
TaqMan or MGB Eclipse platforms at the Core Genotyping Facility
of the Division of Cancer Epidemiology and Genetics, NCI
(Table 1). Assay conditions are available at http://snp500cancer.
nci.nih.gov (Packer et al, 2006). When possible, rs numbers based
on the dbSNP database are indicated (http://www.ncbi.nlm.nih.
gov/SNP). If an rs number has not yet been assigned, an E number
(e.g. E3675_301) is provided, based on nomenclature from the
SNP500Cancer project (Packer et al, 2006). Single nucleotide
polymorphism locations were determined using the guidelines of
the Human Genome Variation Society (den Dunnen and
Antonarakis, 2001).
A total of 100 duplicate DNA pairs were X98% concordant for
each SNP with the exception of TERF1 IVS9-163T4C (rs3863242,
97%) and TERT Ex2-659G4A (rs2736098, 94%). Genotypes were
called for 498% of all SNPs. Genotype frequencies for all loci were
in Hardy–Weinberg equilibrium among controls.
Single nucleotide polymorphism selection
Initial SNP selection criteria included MAF greater than 5% in
Caucasians from SNP500 Cancer (n¼31), even spacing across the
gene, SNPs with potential functional implications and/or patterns
of nucleotide diversity and linkage disequilibrium (LD) previously
determined through extensive re-sequence analysis (Savage et al,
2005; Packer et al, 2006) and assay availability at the time of SNP
selection. The SNPs selected using these criteria were evaluated as
haplotype-tagging SNPs compared with all common SNPs
identified in the prior re-sequence analysis using tagSNPs (Stram,
2004) and TagZilla (http://tagzilla.nci.nih.gov/). R
2
H was the
pairwise correlation coefficient between SNPs determined by these
programs. SNPs with R
2
H X0.8 were considered highly correlated.
TEP1 (54 exons, 40.7 kilobase pairs (kbp)) has minimal LD and
eight common SNPs in the 31 SNP500 Caucasians. The five TEP1
SNPs genotyped (Table 1) gave an R
2
H of 0.84, indicating
representative coverage of common genetic variation across
TEP1. TERF1 (10 exons, 15.3kbp) has very limited nucleotide
diversity with only four common SNPs in SNP500 Caucasians
between introns 7 and 9 (Savage et al, 2005). Three of these SNPs
were genotyped and very good correlation for the fourth SNP was
noted, R
2
H¼1.0. TERF2 (10 exons, 30.3kbp) has only four common
SNPs between introns 1 and 8 and a very small common haplotype
block between introns 6 and 7 (Savage et al, 2005). TERF2
IVS6þ27G4A and IVS7-42T4C were highly correlated with the
other SNP in this block, TERF2 IVS8þ95T4C (E3675_301)
(R
2
H40.8), but did not cover the SNP in intron 1 (TERF1 IVS1-
5C4T, E5055_301), which only had a MAF of 5% in SNP500
Caucasians. Studies of genetic variation in TERT (41.9kbp, 16
exons) are complex due to low nucleotide diversity and limited LD
(Savage et al, 2005). The 10 SNPs genotyped in our study spanned
43kbp from  1654A4G to Ex16þ203C4T and were representa-
tive of common genetic variation, R
2
H¼0.63. We were unable to
genotype TERT Ex14þ7C4T (E3661_301, H1001H) due to lack of
assay availability, which would have increased the R
2
H to 0.83;
however, we did genotype Ex16þ203C4T (rs2853690), which was
only 1776bp 30 of TERT Ex14þ7C4T. The four SNPs genotyped
in POT1 (17 exons, 74.7kbp) spanned 73.1kbp ( 1386G4A
through IVS13-98T4G), a region with strong LD and 11 common
SNPs in SNP500 Caucasians (Savage et al, 2005). These SNPs
(Table 1) were good representatives of common genetic variation
across POT1, R
2
H¼1.0.
Statistical analyses
Odds ratios (OR) and 95% confidence intervals (CI) from logistic
regression models with dummy variables for matching factors (age
in 5-year categories and study site (Warsaw or Ło ´dz ´ )) were used
to estimate relative risks for the genotypes examined. The
association between genotypes and breast cancer risk was tested
using a 2 degrees of freedom (df) likelihood ratio test and a trend
test. Heterogeneity of genotype ORs among groups of women
defined by age categories and family history of breast cancer in
first-degree relatives were evaluated by introducing interaction
terms in logistic regression models. A positive family history was
defined for women reporting one or more first-degree relatives
diagnosed with breast cancer in the study questionnaire. An
additive genetic model was assumed in interaction analyses. Age
was considered as a continuous variable in tests for genotype–age
interactions. Haplotypes were constructed for cases and controls
using PHASE v2.1 (Stephens et al, 2001; Stephens and Donnelly,
2003) and HaploStats (Lake et al, 2003). The global case–control
permutation test was performed using PHASE v2.1 (Stephens et al,
2001; Stephens and Donnelly, 2003). HaploStats (Lake et al, 2003)
was used also to determine the global score P-value, haplotype
frequencies, ORs and 95% CIs.
RESULTS
Most cases (74%) and controls (69%) in the study were
postmenopausal, and cases were diagnosed at an average age
(standard deviation) of 56 (710) years. The established risk
factors were associated with breast cancer risk in comparable
direction with similar estimates of magnitude reported by others
(Garcia-Closas et al, 2006b).
Case–control analyses showed no statistically significant
associations between the 24 SNPs in TEP1, TERF1, TERF2, TERT
and POT1 and risk of breast cancer (Table 1). Specific haplotypes
derived from the evaluated SNPs were also not associated with
increased risk of breast cancer in this study (data not shown).
There were no statistically significant associations among age, SNP
and breast cancer risk (Supplementary Table 1).
Case–control analyses suggested inverse associations between
homozygous variants of TERT and breast cancer risk at two SNP
sites, TERT-1654A4G (OR 0.85, 95% CI 0.72–1.02) and TERT
Ex2-659G4A (A305A) (OR 0.76, 95% CI 0.58–1.00) (Table 1). The
inverse association of TERT Ex2-659G4A (A305A) and two other
linked TERT SNPs appeared to be limited to individuals with a
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sTable 1 Association between 24 single nucleotide polymorphisms in five genes important in telomere biology and breast cancer risk among cases and
controls
Controls Cases
Gene SNP
a Genotype N % N % OR 95% CI P-value P trend
TEP1 Ex1-222 T4C TT 1089 48 959 49 1.00
S116P TC 972 43 831 42 0.97 0.86 1.11 0.68
Rs1760897 CC 203 9 183 9 1.02 0.82 1.27 0.84 0.93
Ex4+51 C4A CC 1514 67 1318 67 1.00
N307K CA 657 29 572 29 1.00 0.87 1.14 0.96
rs1760898 AA 89 4 75 4 0.96 0.70 1.32 0.80 0.85
IVS13+84T4C TT 795 35 712 36 1.00
rs872072 TC 1078 47 928 47 0.97 0.84 1.10 0.61
CC 413 18 337 17 0.91 0.77 1.09 0.32 0.32
Ex24+49 T4C TT 625 28 503 26 1.00
S1195P TC 1096 48 967 49 1.10 0.95 1.27 0.22
rs1760904 CC 540 24 495 25 1.14 0.97 1.35 0.12 0.12
Ex45+36 G4A GG 1433 63 1279 64 1.00
V2214I GA 760 33 616 31 0.91 0.79 1.03 0.14
rs1713449 AA 88 4 92 5 1.18 0.87 1.60 0.28 0.66
TERF1 IVS7+82C4T CC 1360 60 1146 58 1.00
E3663_301 CT 812 36 731 37 1.07 0.94 1.21 0.31
TT 106 5 106 5 1.19 0.89 1.57 0.24 0.15
IVS8-124G4A GG 983 44 836 43 1.00
rs2306494 GA 1017 45 885 45 1.02 0.90 1.17 0.72
AA 254 11 225 12 1.05 0.86 1.28 0.65 0.61
IVS9-163T4C TT 754 32 740 34 1.00
rs3863242 TC 1152 49 1060 48 0.93 0.82 1.06 0.30
CC 437 19 401 18 0.93 0.79 1.11 0.43 0.35
TERF2 IVS6+27G4A GG 1603 70 1389 70 1.00
E3673_301 GA 612 27 535 27 1.01 0.88 1.16 0.88
AA 63 3 50 3 0.92 0.63 1.34 0.66 0.90
IVS7-42T4C TT 1081 47 894 45 1.00
rs251796 TC 960 42 873 44 1.10 0.97 1.25 0.13
CC 242 11 218 11 1.09 0.89 1.34 0.39 0.17
TERT  1654A4G AA 702 31 664 33 1.00
rs2736109 AG 1132 50 963 49 0.90 0.78 1.03 0.13
GG 443 19 357 18 0.85 0.72 1.02 0.08 0.06
 1381C4T CC 695 29 634 29 1.00
rs2735940 CT 1167 49 1121 51 1.05 0.92 1.20 0.46
TT 498 21 447 20 0.98 0.83 1.15 0.78 0.87
 967T4C TT 1671 73 1409 72 1.00
rs7712562 TC 556 24 510 26 1.09 0.94 1.25 0.24
CC 47 2 47 2 1.17 0.77 1.76 0.46 0.18
 244C4T CC 1224 54 1095 55 1.00
rs2853669 CT 900 39 766 39 0.95 0.84 1.08 0.42
TT 158 7 124 6 0.87 0.68 1.11 0.27 0.22
Ex2-659G4A GG 1313 58 1171 60 1.00
A305A GA 811 36 699 36 0.97 0.85 1.10 0.59
rs2736098 AA 141 6 97 5 0.76 0.58 1.00 0.05 0.11
IVS2-4601C4T CC 1082 47 915 46 1.00
rs2736099 CT 957 42 857 43 1.05 0.93 1.20 0.42
TT 241 11 212 11 1.04 0.84 1.27 0.73 0.51
IVS2-4455C4T CC 890 39 738 37 1.00
rs2853677 CT 1062 47 950 48 1.08 0.94 1.23 0.27
TT 330 14 294 15 1.07 0.89 1.29 0.48 0.34
IVS3-24T4C TT 1731 76 1495 75 1.00
rs13167280 TC 518 23 460 23 1.03 0.89 1.19 0.71
CC 36 2 31 2 0.99 0.61 1.61 0.97 0.77
IVS10+269C4T CC 936 41 818 41 1.00
rs2075786 CT 1062 47 918 46 0.99 0.87 1.13 0.93
TT 283 12 244 12 0.99 0.82 1.21 0.95 0.93
Ex16+203C4T CC 1660 73 1454 74 1.00
rs2853690 CT 561 25 467 24 0.95 0.82 1.09 0.45
TT 49 2 43 2 1.00 0.66 1.52 0.99 0.55
POT1  1386G4A GG 966 42 851 43 1.00
E5047_301 GA 1055 46 913 46 0.98 0.86 1.11 0.74
AA 256 11 221 11 0.98 0.80 1.20 0.84 0.76
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 1381C4T (OR 0.73, 95% CI 0.53–1.00),  244C4T (OR 0.66,
95% CI 0.46–0.95), and Ex2-659G4A (A305A) (OR 0.57, 95% CI
0.39–0.84) (Table 2 and Supplementary Table 2). These SNPs were
not significantly related to family history of cancer among the
control population, and analyses of breast cancer cases with a
family history of breast cancer compared with all controls,
regardless of family history, produced similar results (data not
shown). These three SNPs appeared to be in LD by D0, but only
 244C4T and Ex2-659G4A were strongly correlated with R
2
H of
0.79. TERT-1381C4T,  244C4T, and Ex2-659G4A had high
pairwise D0 values, but the R
2
H showed that only  244C4T and
Ex2-659G4A were highly correlated. This suggests that the
associations seen in TERT  1381C4T may not be related to the
effects of LD between this SNP,  244C4T and Ex2-659G4A.
However, the statistical association seen in  244C4T and Ex2-
659G4A could be because they are highly correlated, and in effect,
measure the same risk marker.
Haplotype analyses were performed for all SNPs studied in
TERT and for each of the two major haplotype blocks in TERT
(block 1:  1654A4G,  1381C4T,  967T4C,  244C4T and
Ex2-659G4A, block 2: IVS10þ269C4T and Ex16þ203C4T).
There were no significant associations for haplotypes in the
primary case–control analysis (data not shown). However, a block
1 haplotype (ATCCA) in TERT was associated with protection
from breast cancer when only individuals with a family history of
breast cancer were studied (OR 0.61, 95% CI 0.38–0.97, P¼0.034).
In addition, women with a family history also showed a
borderline statistically significant positive association between
TERF2 IVS-42T4C variant alleles and breast cancer risk (OR 1.57,
96% CI 0.97–2.55, P interaction 0.06). No other associations
were significantly modified by family history of breast cancer
(Supplementary Table 2).
DISCUSSION
To our knowledge, this is the first study to investigate genetic
variation within genes important in telomere biology (POT1, TEP1,
TERF1, TERF2 and TERT) and breast cancer risk. The SNPs
genotyped were representative of common genetic variation across
the genomic region of interest, and showed no significant overall
associations with breast cancer risk. However, data suggested
association between variants in TERT among women with a
positive family history of breast cancer.
TERT Ex2-659G4A showed a borderline statistically significant
association with a reduced risk of breast cancer in analysis of all
cases and controls, which appeared to be stronger for individuals
with a family history of breast cancer. Similar associations of two
other SNPs,  1381C4T and  244C4T, in individuals with a
Table 1 (Continued)
Controls Cases
Gene SNP
a Genotype N % N % OR 95% CI P-value P trend
IVS6-33G4A GG 968 43 847 43 1.00
rs7784168 GA 1052 46 906 46 0.98 0.86 1.12 0.77
AA 249 11 220 11 1.01 0.82 1.24 0.94 0.94
IVS12-111G4A GG 1260 53 1154 52 1.00
rs10263573 GA 914 39 897 41 1.07 0.95 1.21 0.25
AA 185 8 155 7 0.91 0.73 1.15 0.44 0.86
IVS13-98T4G TT 909 39 861 39 1.00
rs10250202 TG 1111 47 1026 47 0.97 0.86 1.10 0.65
GG 332 14 314 14 1.00 0.84 1.20 0.98 0.88
Abbreviations: N¼number of individuals with genotype data; OR¼odds ratio; CI¼confidence interval, UK¼unknown. Differences between total number of cases and
controls and subjects shown in table are due to missing genotype information.
aThe genomic location of the SNP is determined using guidelines from the Human Genetic
Variation Society (den Dunnen and Antonarakis, 2001). If an rs number from the NCBI’s dbSNP database is not available, the SNP is designated by an E number from the NCI’s
SNP500Cancer database (http://snp500cancer.nci.nih.gov).
Table 2 Association between selected single nucleotide polymorphisms in TERF2 and TERT and breast cancer risk among cases and controls, stratified by
family history of breast cancer in first-degree female relatives
Homozygous common Heterozygous Homozygous variant Per minor allele relative risk
Gene SNP
Family
history Controls Cases Controls Cases Controls Cases OR 95% CI P-value P interaction
TERF2 IVS6+27G4A No 1496 1243 592 482 60 46 0.97 0.86 1.10 0.67
E3673_301 Yes 107 146 20 53 3 4 1.57 0.97 2.55 0.07 0.06
TERT  1654A4G No 662 598 1067 857 415 324 0.92 0.85 1.01 0.09
rs2736109 Yes 40 66 65 106 28 33 0.86 0.63 1.18 0.35 0.67
 1381C4T No 661 557 1093 1001 469 412 1.02 0.94 1.11 0.63
rs2735940 Yes 34 77 74 120 29 35 0.73 0.53 1.00 0.05 0.04
 244C4T No 1159 971 843 694 148 116 0.97 0.88 1.07 0.56
rs2853669 Yes 65 124 57 72 10 8 0.66 0.46 0.95 0.03 0.05
Ex2-659G4A No 1243 1037 761 634 130 93 0.96 0.86 1.07 0.44
A305A rs2736098 Yes 70 134 50 65 11 4 0.57 0.39 0.84 0.004 0.01
IVS2- No 1023 810 898 768 227 201 1.06 0.97 1.17 0.22
4601C4T rs2736099 Yes 59 105 59 89 14 11 0.75 0.53 1.06 0.10 0.06
Differences between total number of cases and controls and subjects shown in table are due to missing genotype information.
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was noted to have increased telomerase activity related to the T
allele in a recent study of non-small cell lung cancer (Hsu et al,
2006). TERT  1381C4T also appears to be a functional SNP.
Studies of promoter function at this site (noted at  1327 by the
authors, but with the same rs number, rs2735940) suggested longer
telomere length in with TT homozygotes compared with CC
(Matsubara et al, 2006). Our findings suggested that variants in
TERT could have an effect in individuals already at increased
genetic risk of breast cancer, although the number of individuals
with a family history of breast cancer was small.
TERF2 IVS6þ27G4A (E3673_301) was also associated with a
reduced risk of breast cancer in individuals with a family history of
breast cancer, however, the functional significance of the SNP is
unknown. It does not appear to affect an intron–exon splice site
(Conde et al, 2004).
The SNPs evaluated in this study were chosen based on previous
knowledge of common genetic variation resulting from re-
sequence analysis, captured most of the common variation in the
five studied genes (i.e. POT1, TEP1, TERF1, TERF2 and TERT), and
could be related to breast cancer risk based on the role suggested
for telomere biology in this disease (Baykal et al, 2004; Wacholder
et al, 2004; Savage et al, 2005). Although associations with less
common SNPs are possible, our data indicate that common
variation in these genes is unlikely to substantially affect overall
breast cancer risk. The associations of TERT  1381C4T,
 244C4T, Ex2-659G4A and the corresponding haplotype in
individuals with a family history of breast cancer are intriguing
and warrant follow-up in independent studies.
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